Table 1 Phospholipids for cancer diagnosis and prognosis
From: Cancer metabolites: promising biomarkers for cancer liquid biopsy
Author | Year | Cancer Type | Sample Type | Method | Lipid metabolites | Effect | Ref |
|---|---|---|---|---|---|---|---|
His, M., et al. | 2019 | Breast cancer | Blood | MS, targeted | PC ae C36:3, PC aa C36:3, PC ae C34:2, PC ae C36:2, PC ae C38:2 | Breast cancer risk prediction | [38] |
Han, X., et al. | 2020 | Lung cancer | Blood | UPLC-MS, targeted | Cer 36:1–3, Cer 38:1–3, SM 36:1–2, LPC 16:1 | EGFR-TKI therapeutic efficacy evaluation | [39] |
Rohnisch, H. E., et al. | 2020 | Prostate cancer | Blood | MS and NMR, targeted | LPC C17:0, LPC C20:3, LPC C20:4, PC ae C38:3, PC ae C38:4, PC ae C40:2 | Prostate cancer risk assessment | [40] |
Jiang, N., et al. | 2021 | Papillary Thyroid Cancer | Blood | UPLC-MS,untargeted | GlcCer(d14:1/24:1), PE(18:1/18:1), SM(d16:1/24:1), SM(d18:1/15:0), SM(d18):1/16:1) | Papillary Thyroid Cancer Diagnosis | [41] |
Wang, G., et al. | 2021 | Pancreatic ductal adenocarcinoma | Blood | LC–MS, untargeted and targeted | DG: 18:1–18:1; LPCs: 14:0, 16:0, 18:1, 20:4; PCs: 16:0–16:0, 16:0–18:1, 18:0–18:2, 18:0–20:3, 16:0–22:5, 18:0–22:5, and O-16:0–18:2; LPE: 22:4; PE: 16:0–18:2; SM: d18:1/18:0, d18:2/24:1, d18:2/24:2 | PDAC detection | [42] |
Wang, G., et al. | 2022 | Lung cancer | Blood | LC–MS, untargeted and targeted | PC16:0–18:1, PC 16:0–18:2, PC 18:0–18:1, PC 18:0–18:2, PC 16:0–22:6 | Early-stage lung cancer detection | [43] |